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Original Article

Assessing the Associations of Sodium Intake With
Long-Term All-Cause and Cardiovascular Mortality in a
Hypertensive Cohort
Pamela Singer,1 Hillel Cohen,2 and Michael Alderman2
background
Although higher sodium intake is known to increase blood pressure, its
association with cardiovascular mortality is less established. We examined the association of baseline sodium intake in a hypertensive cohort
with all-cause and cardiovascular mortality over a mean follow-up of
18.6 years.
methods
Three thousand five hundred five subjects were participants in a worksite hypertension program. Sodium intake was estimated by 24-hour
urine excretion. Mortality data were obtained from the US National
Death Index. Unadjusted and multivariable-adjusted associations
between sodium quartiles (quartile I (QI) to quartile IV (QIV)) and mortality were assessed using Cox models.
results
Estimated mean ± SD sodium intake was 130 ± 69 mmol overall
(55 ± 20 mmol in QI; 220 ± 56 mmol in QIV). Baseline systolic blood pressure did not vary significantly between groups. Last available mean
systolic blood pressure was highest in QI and lowest in QIV (137 ± 16

vs. 134 ± 14 mm Hg; P = 0.009). Overall there were 1,013 deaths (399
cardiovascular). Unadjusted models exhibited significant inverse relationships between sodium and mortality outcomes. In adjusted models, sodium intake was not significantly associated with cardiovascular
mortality (QI vs. QIV: hazard ratio (HR) = 1.00; 95% confidence interval (CI) = 0.71–1.42; P = 0.99). A borderline significant direct association with all-cause mortality was observed (QI vs. QIV: HR = 0.81; 95%
CI = 0.66–1.00; P = 0.05) driven partly by noncardiovascular deaths.

conclusions
Our study found no significant association between sodium intake and
cardiovascular outcomes, although a significant association with allcause mortality was observed. Although these findings suggest that
sodium may not have a strong relationship with cardiovascular mortality, the inconsistent results cast doubt on whether a single measurement can reliably predict mortality over a prolonged follow-up period.
Keywords: blood pressure; epidemiology; hypertension; mortality; sodium.
doi:10.1093/ajh/hpu141

Hypertension affects approximately 30% of all US adults1
and is the leading risk factor for cardiovascular morbidity
and mortality.2 Although antihypertensive medication is the
mainstay of blood pressure (BP) control, dietary sodium
restriction has been widely recommended as a public health
measure for both prevention and treatment of hypertension.3 Sodium restriction has been found to lower mean
BP,4–6 with a recent Cochrane review indicating an average
systolic BP (SBP) reduction of 3.5% in hypertensive patients
when sodium intake was reduced by 125 mmol/day.7
At the same time, controversy exists on whether this
sodium–BP effect actually translates to cardioprevention
because intensive sodium restriction may have adverse
effects on insulin resistance, triglycerides, and sympathetic
nervous system activation.7,8 Studies directly examining the
association between sodium intake and cardiovascular outcomes have produced conflicting results, with some finding

a direct association, some showing an inverse or J-shaped
curve, and others finding no relation to cardiovascular disease mortality. The lack of a consistent association is highlighted by the recent Institute of Medicine report,9 which
concluded that the available data preclude a recommendation to restrict sodium to <2,300 mg per day, as well as a
recent meta-analysis demonstrating no association between
reduced sodium intake and cardiovascular mortality despite
a significant reduction in BP.10 Average sodium intakes vary
widely across geographic locales, and differences among the
populations studied may partially account for the seemingly inconsistent results.11–32 This variation underscores the
importance of population-specific studies.
In the United States, an adverse association of lower
sodium intake with cardiovascular outcomes in a group of
healthy hypertensive patients was reported in 1995. During
an average of 3.8 years of follow-up, with a mean sodium
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intake of 115 mmol, an inverse association with myocardial
infarction (MI) was found.13 Our study describes the association of sodium intake with long-term all-cause and cardiovascular mortality in this same cohort, now after nearly
20 years of mean follow-up. This represents the longest follow-up to date of baseline sodium excretion with mortality
outcomes in hypertensive subjects.
METHODS
Study population

Patient recruitment methods have been described in detail
elsewhere.33 Briefly, participants were individuals in a unionsponsored, worksite hypertension program in New York City
between 1978 and 1999. Entry criteria were an SBP ≥140 mm
Hg (≥160 mm Hg before Joint National Committee 5), diastolic BP (DBP) ≥90 mm Hg (≥95 mm Hg before Joint National
Committee 5), or being on antihypertensive medication at
the time of screening. After a medication washout period of
3–4 weeks, a pretreatment study visit was performed. Three
BP readings using a standard sphygmomanometer were
taken, the last 2 of which were averaged for the visit reading.
Laboratory analyses, including a 24-hour urine collection,
were obtained at this visit. Although some laboratory testing
was repeated at multiple points throughout follow-up, a urine
collection was obtained only at baseline. Antihypertensive
medications were prescribed as needed throughout the period
of study participation. Medication prescription generally followed Joint National Committee recommendations but was
ultimately at the discretion of the physician, and from 1981
to 1988, a subset of participants were randomly assigned to
initial monotherapy of a diuretic or β-blocker.34 The last BP
available was the last one recorded in the program.
Sodium measurement

A single 24-hour urine collection was obtained at the pretreatment study visit after the medication washout period.
Subjects were instructed to follow their usual diet while avoiding “excessively salty foods” for a period of 4–5 days preceding the collection. The first void on the day of collection was
discarded, and that of the following day was included in the
measurement. Urine sodium was analyzed using a flame photometer (Instrumentation Laboratories, Bedford, MA, through
1985), or ion-selective electrode (Beckman Astra, Brea, CA).13
Endpoints

Mortality data were obtained using National Death Index
Plus and the Social Security Administration Death Master
File. Mortality data were available through August 2009.
Causes of death were categorized as coronary artery disease,
including MI, ischemic heart disease, heart failure, and
hypertensive heart disease (International Classification of
Diseases, Ninth Revision (ICD-9): 402.9, 410–414.9, 427.5,
429.2; International Classification of Diseases, Tenth Revision
(ICD-10): I10–11.9, I13–I13.2, I20–I25.9, I46–I46.9);
stroke (ICD-9: 434–434.9, 436–438.9; ICD-10: I61–I64.9);
other cardiac causes (ICD-9: 390–459.9; ICD-10: I00–I99
336 American Journal of Hypertension 28(3) March 2015

excluding those listed above); noncardiovascular causes, of
which approximately 50% were cancer deaths (ICD-9: 140–
239; ICD-10: C00–D49); and cause of death unknown.35
Unknown causes of death primarily consisted of those after
2007, for which National Death Index ICD codes were not
available. For outcome analysis, all cardiovascular mortality included death from coronary artery disease, stroke,
and other cardiac causes. Limited cardiovascular mortality
included only MI, ischemic or hypertensive heart disease,
and heart failure, while excluding stroke and other cardiac
causes, which were thought could differ in their relationship
to sodium intake.
Statistical analysis

Values of 24-hour urine sodium were divided into sexspecific quartiles, in which men and women were first
divided into respective sodium quartiles, which were then
combined, such that quartile I (QI) contained the lowest
quartile, respectively, of male values and female values, and
so on. Units of urinary sodium were expressed in millimoles per 24 hours, with 1 mmol equal to 23 mg of sodium.
Potential covariables and confounders were identified based
on prior literature and biologic plausibility, and bivariable
analyses were analyzed using analysis of variance or χ2 testing as appropriate. Estimated glomerular filtration rate was
measured using the Chronic Kidney Disease—Epidemiology
formula.36 Continuous variables were log-transformed as
needed to meet normality assumptions. Unadjusted and
adjusted Cox proportional hazards were performed to
examine the association of 24-hour urine sodium quartiles
with mortality. Quartile IV (QIV) was used as the reference
category in all models. A backwards elimination approach
was used to arrive at reduced models, and variables found
to be independent predictors at P < 0.05 or that showed
evidence of confounding the sodium association (change
in hazard ratio (HR) for sodium of >10%) were retained in
the model. In addition, age, race, sex, and body mass index
were forced into all models. A forward stepping procedure
was then applied to all variables that remained in the final
model to assess for confounding. Interactions were checked
using product terms. The proportional hazard assumption was tested using STATA’s goodness-of-fit command,
which examines the proportional hazards assumption for
the overall model as well as for each individual variable as
a time-varying covariable. Models were analyzed using allcause mortality, all cardiovascular mortality, and limited
cardiovascular mortality as outcomes. Subset analyses were
performed as described below. All analyses were performed
using STATA 12.0 (STATA Corp, College Station, TX).
RESULTS
Baseline characteristics

Three thousand five hundred five study participants completed a 24-hour urine collection. Baseline characteristics of
participants are shown in Table 1. The overall mean ± SD
urinary sodium in our cohort was 130 ± 69 mmol (equivalent to approximately 3 grams of sodium, or 7.5 grams of

Sodium and Mortality in Hypertensives
Table 1.

Baseline characteristics by sex-specific urinary sodium quartiles

Characteristic Urine

Quartile I

Quartile II

Quartile III

Quartile IV

sodium, mmol/24 h

(n = 890) 55 ± 20

(n = 876) 102 ± 17

(n = 865) 143 ± 20

(n = 874) 221 ± 56

Male sex
Age, y

564 (63.4)
53.7 ± 9.8

567 (64.7)

552 (63.8)

53.1 ± 9.2

51.5 ± 9.9

559 (64.0)
51.0 ± 9.2

P value

0.95
<0.0001

Race
Black

269 (30.2)

257 (30.5)

264 (30.5)

250 (28.6)

White

282 (31.7)

295 (33.7)

274 (31.7)

256 (29.3)

Hispanic

300 (33.7)

305 (34.8)

309 (35.7)

335 (38.3)

39 (4.4)

18 (2.1)

18 (2.1)

33 (3.8)

Other

0.04

History
MI
Stroke

10 (1.1)

4 (0.5)

9 (1.0)

13 (1.5)

0.20

8 (0.9)

5 (0.6)

8 (0.9)

6 (0.7)

0.80

Angina

30 (3.4)

29 (3.3)

32 (3.7)

27 (3.1)

0.92

DM

36 (4.0)

55 (6.3)

48 (5.6)

52 (6.0)

0.17

13 (1.5)

12 (1.4)

10 (1.2)

19 (2.2)

0.34

Antihypertensive drug use

CKD

329 (37.0)

349 (39.9)

347 (40.2)

307 (35.2)

0.27

Smoking

187 (21.0)

179 (20.4)

165 (19.1)

144 (16.5)

0.08

27.4 ± 4.1

27.8 ± 4.1

28.9 ± 4.5

30.0 ± 4.9

SBP, mm Hg

146.4 ± 18.5

145.3 ± 17.7

145.2 ± 16.5

145.8 ± 16.3

0.41

DBP, mm Hg

93.6 ± 10.0

93.9 ± 9.7

94.1 ± 9.4

95.1 ± 9.6

0.01

BMI, kg/m2

<0.0001

Hematocrit, mg/dl

43.7 ± 4.0

43.5 ± 4.0

43.7 ± 4.1

43.4 ± 4.0

0.37

Cholesterol, mg/dl

223.2 ± 45.2

222.0 ± 43.5

219.4 ± 42.4

218.7 ± 39.8

0.09

Uric acid, mg/dl
Plasma renin activity, ng/ml/h
eGFR, ml/min/1.73 m2
Urine potassium, mmol/24 h
Urine volume, L

5.9 ± 1.5

5.7 ± 1.4

5.7 ± 1.4

5.7 ± 1.4

0.004

1.7 (0.64–3.4)

1.4 (0.56–2.6)

1.4 (0.54–2.6)

1.2 (0.49–2.4)

0.0001

76.5 ± 16.5
49.5 (25.9)
1.2 ± 0.6

77.9 ± 16.6
58.0 (36.8)
1.3 ± 0.6

78.5 ± 16.4
60.6 (23.5)
1.5 ± 0.5

80.6 ± 16.1
69.9 (27.0)
1.7 ± 0.6

<0.0001
<0.0001
<0.0001

Results are reported as mean ± SD, median (nterquartile range), or frequency (%).
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; MI, myocardial infarction; SBP, systolic blood pressure.

salt), with a mean ± SD of 55 ± 20 mmol in the lowest quartile vs. 221 ± 56 mmol in the highest quartile.
The study population was 64% men, with a mean ± SD age
of 52 ± 10 years. Those in the highest sodium quartile were
significantly younger than those in the lowest, although
the mean age at baseline differed by only 2 years. Blacks,
whites, and Hispanics each accounted for approximately
one-third of the study population and were represented
fairly evenly across all sodium quartiles. No significant differences were seen across quartiles with regards to baseline history of cardiovascular disease, diabetes, or chronic
kidney disease. Baseline body mass index was significantly
associated with sodium quartiles. There was no significant
difference in baseline SBP, and although differences in
baseline DBP were statistically significant (P = 0.008), the
mean absolute difference between QI and QIV was small.
Both urine potassium and urine volume were higher in the
higher urinary sodium quartiles, suggesting higher total
daily food intakes.

Follow-up characteristics

The average in-program time was 6.5 ± 4.4 years, with
no significant difference between the sodium quartiles
(P = 0.63). Weight increased over the course of the study,
with an average participant weight gain of 0.9 ± 6.7 kg
between the first and last visits. Those in QIV were significantly heavier than those in QI at last follow-up (86.5 ± 17.2
vs. 77.7 ± 13.5 kg; P < 0.001), however this difference was
similar in magnitude to that at the start of the study.
Last observed creatinine, uric acid, hematocrit (Hct),
blood sugar, and cholesterol did not differ significantly
across sodium quartiles (data not shown). Only baseline
measurements of urine sodium were obtained during the
study, and no repeat measurements were available.
Mean BP decreased in all sodium quartiles throughout
the duration of the study period, with an overall average final
SBP of 136 ± 15 mm Hg and DBP of 84 ± 9 mm Hg. Last available follow-up values revealed the SBP to be highest in QI,
American Journal of Hypertension 28(3) March 2015
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with no significant difference in DBP. Table 2 illustrates the
changes in BP measurements throughout the study period.
At the time of the last program visit, approximately 80%
of study participants were being prescribed at least 1 antihypertensive medication, with 33% having been prescribed
≥3 drugs. There were no significant differences in the number of antihypertensives prescribed at the time of last program visit (mean in Q1 vs. Q4 = 1.65 ± 1.1 vs. 1.72 ± 1.2;
P = 0.51).
Sodium and mortality outcomes

The overall mean length of follow-up, measured as the
time from initial intake to death or last known alive, was
18.6 years. Overall, there were 1,013 deaths, with 287 total
deaths in QI vs. 216 in QIV. Of the total deaths, 399 were due
to cardiovascular causes, with 128 cardiovascular deaths in
QI vs. 78 in QIV. Most deaths occurred among patients after
they were no longer in the worksite program. Approximately
half of noncardiovascular deaths for which the cause was
known were due to cancer. Figure 1 shows details of noncardiovascular causes of death. In unadjusted analysis, lower

Table 2.

sodium intake was consistently associated with a higher
mortality across all outcomes measured. Figure 2 shows
crude mortality data as well as unadjusted HRs for all-cause
and cardiovascular mortality.
Table 3 shows the results of multivariable Cox proportional hazards modeling for all-cause, cardiovascular, limited cardiovascular, and noncardiovascular mortality, and a
survival curve for all cardiovascular mortality is shown in
Figure 3. Although a borderline direct association between
sodium and all-cause mortality was found, no association
between sodium and cardiovascular death was observed.
When cardiovascular deaths were excluded from the model,
results became highly significant QI vs. QIV: HR = 0.57;
P = 0.001), suggesting the overall significance with all-cause
mortality was at least partially driven by noncardiovascular
events. When looking exclusively at cardiovascular deaths
in a noncompeting risk model, urinary sodium was not
significantly associated with all cardiovascular or limited
cardiovascular mortality (QI vs. QIV: HR = 0.86, P = 0.38;
HR = 0.79, P = 0.20, respectively). In a post hoc power analysis, we had >80% power to observe a true, independent population HR for cardiovascular disease mortality of sodium

Relationship of blood pressure to sodium quartiles

Blood pressure parameters

Quartile I

Quartile II

Quartile III

Quartile IV

P value

Systolic

146.4 ± 18.5

145.2 ± 17.7

145.1 ± 16.5

145.8 ± 16.3

Diastolic

93.6 ± 10.0

93.9 ± 9.7

94.1 ± 9.4

95.1 ± 9.6

0.008

No. of hypertensives (%)

745 (84)

727 (84)

744 (87)

756 (87)

0.31

Systolic

141.6 ± 15.9

142.6 ± 16.1

141.2 ± 16.9

140.9 ± 15.8

0.26

Diastolic

89.6 ± 8.8

89.5 ± 9.4

90.0 ± 9.4

90.0 ± 8.5

0.44

Systolic

136.7 ± 15.8

136.2 ± 15.1

135.1 ± 16.0

134.3 ± 14.5

0.006

Diastolic

83.8 ± 9.7

84.1 ± 8.9

84.0 ± 9.5

84.4 ± 9.1

0.57

689 (77)

668 (76)

655 (76)

682 (78)

0.65

Initial
0.41

First follow-up

Final In-Program

No. on medication (%)

Blood pressure is expressed in mm Hg. Data are mean ± SD unless otherwise noted.

Figure 1. Noncardiovascular causes of death (excluding unknown). Abbreviation: GI, gastrointestinal.
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Figure 2. Raw mortality data by sodium quartiles. All-cause mortality (QI vs. QIV: unadjusted hazard ratio (HR) = 1.25; 95% confidence interval
(CI) = 1.05–1.49; P = 0.01); all cardiovascular mortality (QI vs. QIV: HR = 1.61; 95% CI = 1.21–2.13; P = 0.001); limited cardiovascular mortality (QI vs. QIV:
HR = 1.49; 95% CI = 1.08–2.05; P = 0.01); noncardiovascular mortality (QI vs. QIV: HR = 1.02; 95% CI = 0.77–1.35; P = 0.87).

QI to QIV ≤0.85 or ≥1.17 and ≥95% power to detect a true
HR ≤0.80 or ≥1.23.
In examining the potential cause for the difference
between adjusted and unadjusted analysis, a forward modeling technique was used to assess confounding in all variables that remained in the final models. Baseline age was
significantly higher in the lowest sodium quartile (53.7 years
in QI vs. 51 years in QIV), and adjusting for this variable
alone strongly altered the associations seen in the unadjusted analyses. Other variables tested were not shown to
substantially confound this association.
The proportional hazard assumption was tested and was
not violated for any of the final models. To assess the possibility of a J- or U-shaped relation, models were retested
using quartile II (QII) as a reference quartile. No significant
association was found for other quartiles vs. QII for any
mortality outcome tested (overall, cardiovascular, limited
cardiovascular mortality).
Sensitivity analyses

In addition to quartile analysis, sodium was analyzed as
a continuous variable, with similar results. To account for
possible problems with 24-hour urine collections, subset
analyses excluding the top and bottom 1% of urinary sodium
values and excluding those whose calculated creatinine
clearance did not fall within ±35% of estimated glomerular filtration rate were performed and did not substantially
change our results. In light of the study findings of Geleijnse
et al.,22 urine sodium/potassium ratio was also examined and
was not found to be a significant independent predictor of
mortality. Models excluding SBP (due to its potential mediation) and models excluding participants with a baseline BP
<140/90 mm Hg after the medication washout period, who

may not have been truly hypertensive at baseline, similarly
did not affect results.
Discussion

We found a borderline significant association of sodium
intake with all-cause mortality, a highly significant association with non–cardiovascular disease mortality, and no
significant association with cardiovascular outcomes. These
multivariable-adjusted findings were in contrast to unadjusted analyses, in which significant inverse associations
were seen for both all-cause and cardiovascular mortality.
The degree of discrepancy between adjusted and unadjusted
analysis was largely a result of the baseline age difference
between the quartiles, even though the difference in mean
age was small.
This may also explain the discrepant findings with the
earlier report of this cohort,13 which found a significantly
greater risk of MI in men with lower sodium intake. It is
important to note that the earlier study had many more
morbid events than fatalities (221 vs. 61, respectively), and
the effect of age on morbidity may be less prominent than
that on death. Unfortunately, long-term morbidity data
were not available in our study. Furthermore, the follow-up
time in the previous study was substantially shorter, with a
mean of 3.8 years. On a population level, sodium intake has
been shown to be very consistent over prolonged periods
of time,37 but it is unclear whether this is also applicable to
individuals.
Another possible explanation for the lack of significant
association over the long term is the effect of “regression
dilution bias,”38 in which, due to a combination of measurement error and within-individual variance, single measurements of a baseline characteristic tend to underestimate the
American Journal of Hypertension 28(3) March 2015
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Table 3. Adjusted hazard ratios for sodium quartiles with mortality
outcomes, using quartile IV as reference
Mortality outcome

Hazard ratio (95% CI)

P value

All-cause mortalitya(n = 3,052)
QI

0.81 (0.66–1.00)

0.05

QII

0.90 (0.73–1.10)

0.31

QIII

0.88 (0.71–1.09)

0.23

All cardiovascular mortalityb
QI

1.00 (0.71–1.42)

0.99

QII

0.96 (0.68–1.36)

0.82

QIII

1.06 (0.75–1.49)

0.74

Limited cardiovascular mortalityc
QI

0.93 (0.63–1.39)

0.73

QII

0.82 (0.55–1.22)

0.34

QIII

1.06 (0.73–1.55)

0.74

Noncardiovascular mortalityd
QI

0.57 (0.41–0.80)

0.001

QII

0.85 (0.63–1.16)

0.31

QIII

0.80 (0.59–1.10)

0.18

All covariables listed are those at baseline. Backwards elimination
approach was used to arrive at all final models.
Abbreviations: QI, quartile I; QII, quartile II; QIII, quartile III.
aAdjusted for age, sex, race, body mass index (BMI), systolic
blood pressure (SBP), estimated glomerular filtration rate (eGFR),
urine potassium, hematocrit, HxDM, Hx smoking, history of baseline
left ventricular hypertrophy (Hx baseline LVH).
bAdjusted for age, sex, race, BMI, SBP, eGFR, urine potassium,
hematocrit, plasma renin activity, HxDM, Hx smoking, history of
baseline left ventricular hypertrophy.
cAdjusted for age, sex, race, BMI, SBP, urine creatinine, plasma
renin activity, HxDM, Hx smoking, history of baseline left ventricular
hypertrophy.
dAdjusted for age, sex, race, BMI, SBP, hematocrit, urine potassium, HxDM, Hx smoking. Abbreviations: Hx smoking, history of
smoking; HxDM, history of diabetes.

strength of association with an outcome over time. Thus it
remains possible that with multiple measurements a significant association could have been seen, although the magnitude or even direction of such a potential association cannot
be estimated without making assumptions that cannot be
tested.
Finally, during the study the majority of participants
were placed on antihypertensives, with similar declines in
BP throughout the study period. Although it is possible that
attention to BP measurements may have altered participants’
sodium intake, undermining the ability to determine an
association, without repeat measurements it is impossible
to know whether changes in sodium intake differentially
affected those in each quartile.
Despite the nonsignificant cardiovascular findings, a
borderline significant direct association with all-cause
mortality and a strongly significant association with noncardiovascular mortality remain and must be explained.
340 American Journal of Hypertension 28(3) March 2015

Because of the diverse causes of noncardiovascular death, of
which 50% were cancers, and without a mechanism linking
sodium intake to these various causes, it seems more likely
that this represents either a chance finding or latent confounding rather than a causative contribution of sodium to
mortality. Furthermore, analysis of in-program follow-up
data revealed that final in-program SBP was highest in the
lowest sodium quartile. This finding contradicts the presumed mechanism that sodium increases risk of mortality by increasing BP. One potential explanation for all of
these findings together is that sodium intake, although not
the true cause of the association with mortality, is a marker
of overall health behaviors, and that those with the lowest
sodium intakes may have been practicing healthier habits
overall.
Strengths of this study include the long duration of
follow-up and the estimation of sodium intake by urinary
excretion, as opposed to questionnaire or recall methods,
which may be less accurate.39 Other strengths include
the use of a medication “washout” period, ensuring that
baseline sodium measurements were not affected by medication use, and the worksite program design, in which
participants were essentially healthy at entry, reducing
concern for reverse causality.
A possible limitation of the study is the instruction
to avoid “excessively salty food” in the days before the
collection, as patients may have reduced their normal
sodium intake, thereby introducing bias. It is important
to note that the study period predated the mandated use
of nutritional food labeling, therefore attempts to lower
sodium intake over a few days may not have been as easily
achieved as is currently possible.40 If, however, behavioral changes did occur, this may have similarly affected all
quartiles. Although a differential bias affecting primarily those in the higher sodium quartiles is possible, it
would be difficult to assess this in the absence of followup sodium measurements, which is a major limitation of
the study. Although a large study of temporal trends in
sodium intake in the United States found no significant
change over a 40-year period,37 these studies looked at
a population level, and on the individual level, intakes
may have varied substantially. Finally, the healthy worker
effect, participation in an intensive worksite hypertension
program, and lack of knowledge of change in hypertensive treatment after the end of program participation may
reduce the generalizability of our findings.
Taken together, our results indicate that the association
of sodium intake, measured at baseline, is not significantly
associated with long-term cardiovascular outcomes. If such
an association does exist in this population, our data suggest
it is likely to be modest and muted by intervening factors
over the prolonged period of observation. The association
with all-cause mortality found in our study is of borderline
significance, driven in part by noncardiovascular events,
and in the absence of a proposed mechanism of causality
may be a chance association. Further studies with repeated
assessments of sodium excretion may more clearly define
the long-term association between sodium intake and mortality outcomes.

Sodium and Mortality in Hypertensives

Analysis time
Sodium quartile I
Sodium quartile III

Sodium quartile II
Sodium quartile IV

Figure 3. Kaplan–Meier curve of sodium intake vs. all cardiovascular mortality. Note that the y axis ranges from 0.5 to 1.0 for ease of visualization.
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